Connect with us

Politics

Group Behind Denver Psilocybin Decriminalization Takes Its Mission Global

Published

on

It’s been almost three months since Denver voters approved a measure to decriminalize psilocybin mushrooms. And now, the campaign behind that successful initiative is expanding nationally—even globally.

Decriminalize Denver is rebranding as it evolves into SPORE, or the Society for Psychedelic Outreach, Reform and Education. Kevin Matthews, the group’s executive director, told Marijuana Moment in a phone interview that SPORE is “hub for education” that’s simultaneously “working to educate Denver residents” about implementation of local decriminalization while also serving as “advocates for the national conversation.”

“We recognized that there’s a need for a national advocacy group for psilocybin and other psychedelics, and SPORE is going to fill that space,” he said.

To an extent, SPORE will be sharing that space with Decriminalize Nature, the reform organization that advanced a broad psychedelics decriminalization through the Oakland City Council last month and is working to get a similar resolution approved in Berkeley and other cities. Matthews said the difference between the groups mostly comes down to strategy.

“We’re much more interested in localizing the national psychedelics constituency and really supporting people in other areas where they live—either with messaging or best practices,” he said. “If people are running actual campaigns, [SPORE will be] helping with fundraising, finding donors.”

“It’s great that [Decriminalize Nature] is doing their thing and we’re doing ours—and we’re still figuring out how to work together—but a rising tide raises all ships and the more we can collaborate with each other, that’ll make this movement that much more powerful across the country,” he said.

As SPORE navigates the process of gaining 501(c)(3) nonprofit organization accreditation—with later plans to obtain 501(c)(4) status to allow lobbying—it’s already started getting the gears turning in a number of jurisdictions. Matthews said that the group is in talks with activists in Arizona, Missouri, Washington, D.C. and even the United Kingdom.

“This is no longer just a national conversation. It’s 100 percent global.”

Unlike their approach in Denver, which had a singular focus on removing criminal penalties for psilocybin alone, SPORE is open to supporting reform efforts that involve all entheogenic substances, including ayahuasca and ibogaine.

But whereas Decriminalize Nature has so far made such comprehensive psychedelics decriminalization the standard for its reform resolutions, SPORE says it plans to take a more strategic and tailored approach, making sure that wherever activists they support are seeking change, it’s within the realm of political possibility.

“I think Oakland might be one of the few places in the country where they could actually decriminalize all entheogens,” Matthews said. “I don’t really believe that’s something that can happen in a lot more places in the country, especially if you’re working directly with city councils.”

“But we don’t want to limit the scope of our work,” he added. “If individuals choose to work with us who are looking at psilocybin and other substances, then that’s great. We just have to make sure that if we’re going to dedicate time and resources to those organizations that they’ve really done their research and they understand the demographic and what’s actually possible.”

SPORE’s localized reform approach will be complemented by efforts to win favor with federal lawmakers, too. Matthews pointed to an amendment introduced this year by Rep. Alexandria Ocasio-Cortez (D-NY) aimed at promoting research into psychedelics as evidence that the time is ripe for a national dialogue about the issue.

The measure, despite having been overwhelmingly rejected on the House floor, is “a pretty big deal, and this is the kind of thing where we believe drug policy reform should be at the forefront of public discourse during this election cycle considering that the U.S. government spends billions of dollars every year enforcing the drug war,” he said.

“We know it doesn’t work. We know that a majority of our nation’s inmates have mental health issues and substance abuse issues. They’re not getting the help they need,” Matthews said. “In many ways right now this is a very unique opportunity to start really pressing a national conversation.”

“This mental health and addiction crisis is being ignored by most people… If we have a tool like psilocybin that can be used to directly address this issue and actually get people the help they need—that’s either free or doesn’t cost very much—then I think we should go that route because it’s about saving lives now at this point. It’s imperative that we start to really start to change the hearts and minds of individuals all across the country. We’re in an emergency crisis with this.”

Matthews said that SPORE will likely be heading to the nation’s capital in the next few months to provide information to lawmakers and talk to members of what he dubbed the “Psychedelic Caucus”—the 90 representatives who voted in favor of Ocasio-Cortez’s measure.

“We really have a mission to mobilize this psychedelics constituency and see what kind of magic can happen because the health of our culture is at stake and the health of our society is at stake. And this constituency very specifically I think has a lot more political power than people realize,” he said. “If we can mobilize this group of people to create massive change, massive positive change, then we can see a radical transformation of our culture for the better.”

But in the meantime, SPORE will continue to work with Denver officials to ensure that the measure that sparked this national movement is effectively implemented. That will involve educating the local government and law enforcement and working with Denver on cosponsored “front-facing” public service announcements to raise awareness about psilocybin.

“There’s a lot that’s possible,” Matthews said. “Right now, with the public service announcements on the table and potentially receiving some funding from the city of Denver to get those going, which could mean billboards and ads on the back of transit buses.”

He added that he’s especially excited about the city’s review panel, which is “the only government body of its kind in the U.S. that’s geared specifically towards reviewing and assessing the impact of psilocybin decriminalization and potentially exploring what next steps can be.”

“Our work with the city is really setting a precedent for what this looks like moving forward in the country and we’re excited,” Matthews said. “We have more coming up.”

Psychedelics Decriminalization Moves Forward In Cities Around The U.S.

Photo courtesy of Wikimedia/Mädi.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Business

Feds Send Warning Letter To Another CBD Company Over Medical Claims

Published

on

The Food and Drug Administration (FDA) and Federal Trade Commission (FTC) sent a warning letter to a Florida-based CBD company on Tuesday, alleging that the business made several unsanctioned claims about the therapeutic benefits of their products.

The federal agencies accused Rooted Apothecary of unlawfully asserting that their cannabidiol products could treat symptoms of conditions such as ADHD, Parkinson’s disease, ear aches, ADHD and autism. Those claims appeared on the company’s website and social media accounts, they said.

Certain products appeared to be marketed as dietary supplements, which FDA currently prohibits as it works to develop an alternative regulatory scheme for CBD.

“Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance,” Acting FDA Commissioner Ned Sharpless said in a press release. “We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat, or cure a number of diseases or conditions.”

“We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements,” he said. “As we examine potential regulatory pathways for the lawful marketing of cannabis products, protecting and promoting public health through sound, science-based decision-making remains our top priority.”

FTC’s complaint with the company is that it violated a law that requires businesses that advertise medical claims about their products to have “competent and reliable scientific evidence” to back them up, which could include human clinical trials. Making or exaggerating such claims through “a product name, website name, metatags, or other means” without proper evidence is also prohibited.

Rooted Apothecary must respond to the agencies within 15 working days to explain what steps it’s taking to resolve the issues. If the company fails to do so, it is subject to legal action, including the possible seizure of its products or an injunction. It may also have to compensate customers.

FDA emphasized that CBD products—other than the prescription medication Epidiolex, for the treatment of intractable epilepsy—are not currently allowed. But it also reiterated that the agency is in the process of developing rules that could allow for the lawful marketing of the compound.

In April, FDA sent warning letters to three other CBD companies that it said was making unauthorized claims about the medical benefits of their products. FTC also submitted warning letters to three separate CBD companies for allegedly advertising misleading statements about their products last month.

These letters are examples of the agency’s use of enforcement discretion. Former FDA Commissioner Scott Gottlieb, who recently suggested that the federal government should be involved in regulating state marijuana programs, clarified in March that the agency is only going after companies that make especially misleading claims about their products.

Senate Majority Leader Mitch McConnell (R-KY), who championed a provision of the 2018 Farm Bill federally legalizing hemp and its derivatives, has urged FDA to clear a path for the lawful marketing of CBD products by using enforcement discretion while it develops an interim final rule. A bipartisan group of lawmakers made a similar request in a letter sent to the agency last month.

“The FDA is working quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD while using all available resources to monitor the marketplace and protect public health by taking action as needed against companies,” FDA Principal Deputy Commissioner Amy Abernethy said.

“We recognize that there is significant public interest in cannabis and cannabis-derived compounds; however, we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products,” she said. “We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence.”

Hemp Regulations Will Be Issued Within Weeks, Top USDA Official Says

Photo courtesy of Kimzy Nanney.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

GOP Senator Links Medical Marijuana Claims To Tobacco Industry Advertisements

Published

on

Sen. John Cornyn (R-TX) said on Tuesday that claims about the therapeutic potential of marijuana remind him of decades-old tobacco industry advertisements asserting that the product had medical benefits.

In a speech on the Senate floor, Cornyn discussed a hearing that the International Narcotics Control Caucus, which he co-chairs, will hold on Wednesday to explore the public health impacts of cannabis. He said it was especially important to hear from experts about the subject as more states legalize marijuana and members of Congress, as well as Democratic presidential candidates, push to end federal prohibition.

The senator made clear he’s skeptical about marijuana’s health benefits.

“There’s no shortage of people who claim that marijuana has endless health benefits and can help patients struggling from everything from epilepsy to anxiety to cancer treatments,” he said. “This reminds me of some of the advertising we saw from the tobacco industry years ago where they actually claimed public health benefits from smoking tobacco, which we know as a matter of fact were false and that tobacco contains nicotine, an addictive drug, and is implicated with cancers of different kinds.”

“We’re hearing a lot of the same happy talk with regard to marijuana and none of the facts that we need to understand about the public health impact of marijuana use,” he said.

While Cornyn recognized there’s significant support for cannabis reform, he said that ” for the number of voices in support of legalization, there are even more unanswered questions about both the short- and long-term public health effects.”

He expressed concern about increased levels of THC concentration in cannabis products and stated that it’s “true that for some people that marijuana can indeed be addictive.”

“There’s simply a lack of scientific evidence to determine the link between marijuana and various health risks, and that’s something I would think Congress and the American people would want to know before we proceed further down this path,” Cornyn said. “We don’t know enough about how this could impair cognitive function or capacity or increase the risk of mental illness or perhaps serve as a gateway for other drugs that are even more damaging to the health of a young person.”

The senator made similar remarks during a conversation with a former White House drug czar in August. He said it was important to address the public health impacts of cannabis before moving forward with legislation that would protect banks that service marijuana businesses from being penalized by federal regulators.

“With increasing use and a growing number of states giving the green light for marijuana use, we need better answers,” he said.

The surgeon general and the director of the National Institute on Drug Abuse, along with several academics, are scheduled to testify at Wednesday’s hearing.

Senate Hearing To Focus On Marijuana And Health This Week

Photo courtesy of C-SPAN.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Michael J. Fox Parkinson’s Foundation Urges Congress To Pass Three Marijuana Research Bills

Published

on

A leading advocacy group that’s dedicated to finding treatment options for Parkinson’s disease is backing three pieces of marijuana research legislation in Congress.

The Michael J. Fox Foundation (MJFF)—named after the actor, who has Parkinson’s and established the nonprofit—said last week that lifting barriers to cannabis research, including rescheduling the plant under the Controlled Substances Act (CSA), is necessary to promote studies verifying marijuana’s potential therapeutic benefit for conditions such as Parkinson’s patients.

“The MJFF supports increased access to cannabis for medical research. Congress has begun to recognize this need, and there are several bills in the U.S. House and Senate designed to remove barriers that impede safe and legal access to cannabis by medical researchers,” the foundation said on its website. “The MJFF public policy team is tracking these bills and working to educate members of Congress and their staff on their importance to the Parkinson’s community.”

MJFF said it’s in favor of three marijuana bills, which would accomplish the following: 

Medical Cannabis Research Act

—Require the Justice Department to approve additional manufacturers for research-grade cannabis.

—Protect research institutions that conduct studies on marijuana.

—Authorize the U.S. Department of Veterans Affairs (VA) to inform patients about opportunities to participate in federally authorized cannabis studies.

VA Medicinal Cannabis Research Act

—Require VA to conduct studies into the therapeutic potential of marijuana in the treatment of various conditions that commonly afflict veterans such as chronic pain and post-traumatic stress disorder.

Expanding Cannabis Research and Information Act

—Reschedule marijuana from Schedule I to Schedule III under the CSA.

—Free up universities to conduct studies on cannabis by removing certain regulatory requirements.

In a letter to the Senate sponsor of that last piece of legislation, Sen. Dick Durbin (D-IL), in June, the foundation stated that marijuana’s current classification under federal law and the inadequate quality of cannabis grown at the only federally authorized manufacturing facility has meant that “researchers do not have the proper materials to conduct the necessary research.”

The foundation noted that it has submitted comments to the Food and Drug Administration arguing in favor of rescheduling in 2018 and 2019. It also applauded the Drug Enforcement Administration for announcing that it would take steps to approve additional federal cannabis farms for research.

“Current policies hinder comprehensive medical research on cannabis, making it difficult to generate the evidence needed for clear recommendations,” Andrew Koemeter-Cox, MJFF’s associate director of research programs, said. “This is especially problematic when some products may be unsafe for human use and have the potential for adverse interactions with other medications.”

Ted Thompson, the nonprofit’s senior vice president of public policy, said that removing barriers to research “is one way in which Congress can help scientific researchers determine what the benefits of medical cannabis might be for Parkinson’s disease.”

“Our role on the public policy team is to work with Congress and the administration to ensure there is access and funding for research and care initiatives that can benefit people living with Parkinson’s and, right now, that includes access to medical cannabis for research,” he said.

Senate Hearing To Focus On Marijuana And Health This Week

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!